Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Prostate Cancer Metastatic × olaparib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Ovarian Neoplasms 41 Breast Neoplasms 34 Prostatic Neoplasms 16 Triple Negative Breast Neoplasms 15 Neoplasms 11 Fallopian Tube Neoplasms 10 Endometrial Neoplasms 10 Pancreatic Neoplasms 8 Squamous Cell Carcinoma of Head and Neck 7 Small Cell Lung Carcinoma 7 Recurrence 7 Neoplasm Metastasis 5 Carcinoma, Ovarian Epithelial 5 Sarcoma 4 Lung Neoplasms 4 Glioma 4 Glioblastoma 4 Carcinoma, Squamous Cell 4 Advanced Breast Cancer 4 Uterine Cervical Neoplasms 3 Stomach Neoplasms 3 Solid Tumor 3 Head and Neck Neoplasms 3 Fanconi Anemia, Complementation Group D1 3 Carcinoma, Non-Small-Cell Lung 3 Uveal Melanoma 2 Uterine Neoplasms 2 Urinary Bladder Neoplasms 2 Sarcoma, Ewing 2 Neuroendocrine Tumors 2

Interventions

Radiosurgery 5 Androgen Antagonists 4 enzalutamide 2 Prednisone 2 Docetaxel 2 talazoparib 1 sipuleucel-T 1 rucaparib 1 olaparib 1 gallium 68 PSMA-11 1 darolutamide 1 cabazitaxel 1 apalutamide 1 XRP6258 1 Radiotherapy, Image-Guided 1 Radiotherapy 1 Positron Emission Tomography Computed Tomography 1 Pluvicto 1 Lutetium-177 1 Lutetium 1 Lenograstim 1 Hematologic Tests 1 Granulocyte Colony-Stimulating Factor 1 Gonadotropin-Releasing Hormone 1 Abiraterone Acetate 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03434158 2022-11-03

IMANOL

Spanish Oncology Genito-Urinary Group

Phase 2 Completed

Prostate Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡